Rockefeller Financial Services Inc. maintained its position in Sanofi (NYSE:SNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,761 shares of the company’s stock at the end of the second quarter. Rockefeller Financial Services Inc.’s holdings in Sanofi were worth $468,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in SNY. Fisher Asset Management LLC raised its stake in shares of Sanofi by 8.1% in the second quarter. Fisher Asset Management LLC now owns 13,638,458 shares of the company’s stock worth $653,419,000 after buying an additional 1,022,953 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Sanofi by 22.2% in the first quarter. Wells Fargo & Company MN now owns 4,492,719 shares of the company’s stock worth $203,296,000 after buying an additional 815,820 shares during the last quarter. Global Financial Private Capital LLC acquired a new stake in shares of Sanofi during the first quarter worth about $35,034,000. Karp Capital Management Corp acquired a new stake in shares of Sanofi during the first quarter worth about $26,174,000. Finally, Bank of America Corp DE raised its stake in shares of Sanofi by 8.2% in the first quarter. Bank of America Corp DE now owns 7,531,334 shares of the company’s stock worth $340,792,000 after buying an additional 572,652 shares during the last quarter. 9.97% of the stock is currently owned by institutional investors and hedge funds.
Shares of Sanofi (NYSE SNY) traded down 1.10% during trading on Friday, hitting $47.56. The stock had a trading volume of 1,977,342 shares. The stock has a market cap of $120.11 billion, a price-to-earnings ratio of 11.32 and a beta of 0.89. The stock’s 50-day moving average price is $48.14 and its 200 day moving average price is $45.66. Sanofi has a one year low of $36.81 and a one year high of $50.24.
Sanofi (NYSE:SNY) last posted its quarterly earnings data on Friday, April 28th. The company reported $0.76 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.73 by $0.03. The company had revenue of $8.65 billion during the quarter, compared to analyst estimates of $8.40 billion. Sanofi had a net margin of 26.55% and a return on equity of 25.89%. The business’s revenue was up 1.2% on a year-over-year basis. On average, equities analysts forecast that Sanofi will post $3.20 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This article was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://stocknewstimes.com/2017/07/30/rockefeller-financial-services-inc-holds-position-in-sanofi-nysesny-updated.html.
SNY has been the topic of a number of analyst reports. Zacks Investment Research lowered Sanofi from a “buy” rating to a “hold” rating in a research report on Tuesday, April 25th. J P Morgan Chase & Co reaffirmed a “sell” rating on shares of Sanofi in a research report on Wednesday, April 5th. HSBC Holdings plc lowered Sanofi from a “hold” rating to a “reduce” rating in a report on Friday, April 7th. TheStreet raised Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Finally, Argus boosted their price objective on Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $67.67.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
